Author Correction: Safety and immunogenicity of a tetravalent and bivalent SARS-CoV-2 protein booster vaccine in men
Nat Commun
.
2024 Jan 8;15(1):369.
doi: 10.1038/s41467-024-44729-x.
Authors
Suad Hannawi
1
,
Linda Saf Eldin
2
,
Alaa Abuquta
1
,
Ahmad Alamadi
3
,
Sally A Mahmoud
4
,
Aala Hassan
1
,
Shuping Xu
5
,
Jian Li
5
,
Dongfang Liu
5
,
Adam Abdul Hakeem Baidoo
5
,
Dima Ibrahim
6
,
Mojtaba Alhaj
7
,
Yuanxin Chen
5
,
Qiang Zhou
5
,
Liangzhi Xie
8
9
Affiliations
1
Internal Medicine Department, Al Kuwait-Dubai (ALBaraha) Hospital, Dubai, United Arab Emirates.
2
General Surgery Department, Al Kuwait-Dubai (ALBaraha) Hospital, Dubai, United Arab Emirates.
3
Ear, Nose and Throat Department (ENT), Al Kuwait-Dubai (ALBaraha) Hospital, Dubai, United Arab Emirates.
4
Biogenix labs, G42 Healthcare, Dubai, United Arab Emirates.
5
Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing, China.
6
Infectious Diseases Department, Burjeel Medical City, Abu Dhabi, United Arab Emirates.
7
Research Department, Burjeel Medical City, Abu Dhabi, United Arab Emirates.
8
Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing, China. LX@sinocelltech.com.
9
Cell Culture Engineering Center, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. LX@sinocelltech.com.
PMID:
38191554
PMCID:
PMC10774261
DOI:
10.1038/s41467-024-44729-x
No abstract available
Publication types
Published Erratum